Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4884009 | 0.88 | CNR1 (0.76) | CNR1CNR2 | |
| SCHEMBL4886113 | 0.86 | CNR1 (0.72) | CNR1CNR2 | |
| SCHEMBL11160502 | 0.83 | CNR2 (0.59) | CNR1CNR2 | |
| SCHEMBL11160476 | 0.83 | CNR2 (0.59) | CNR1CNR2 | |
| SCHEMBL10922725 | 0.83 | CNR2 (0.59) | CNR1CNR2 | |
| SCHEMBL11169755 | 0.83 | CNR2 (0.59) | CNR1CNR2 | |
| SCHEMBL4881841 | 0.83 | CNR2 (0.59) | CNR1CNR2 | |
| SCHEMBL11164590 | 0.83 | CNR2 (0.59) | CNR1CNR2 | |
| SCHEMBL4888568 | 0.82 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL3855592 | 0.81 | CNR2 (0.57) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262011-A1 | Modulator | UCL BIOMEDICA PLC (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080262011-A1 | Modulator | UCL BIOMEDICA PLC (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080262011-A1 | Modulator | UCL BIOMEDICA PLC (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1853538-A2 | MODULATOR | UCL Biomedica plc (GB) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006067450-A2 | MODULATOR | UCL BIOMEDICA PLC (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262011-A1 | Modulator | CHRNA10, CNR1, CHRNA9 | CNR1 2/4885CNR2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.